Table 2.
Group A | Group B | P value | |
---|---|---|---|
Patients, n | 146 | 146 | |
Genderb | |||
Male | 96 (65.8%) | 101 (69.2%) | 0.625 |
Female | 50 (34.2%) | 45 (30.8%) | |
Age median (min–max)d | 53 (21–80) | 52 (21–79) | 0.895 |
BMI (kg/m2)c | 24.7 ± 2.5 | 24.8 ± 2.3 | 0.875 |
Symptom | |||
Lumbagoe | 100 (68.5%) | 103 (70.5%) | 0.795 |
Symptomlesse | 40 (27.4%) | 37 (25.3%) | 0.787 |
Pyrexiae | 14 (9.6%) | 15 (10.3%) | 1.000 |
Vomitinge | 28 (19.2%) | 27 (18.5%) | 1.000 |
Hematuriae | 17 (11.6%) | 17 (11.6%) | 1.000 |
Treatment history | |||
ESWLe | 10 (6.8%) | 11 (7.5%) | 1.000 |
Ureteroscopic lithotripsye | 11 (7.5%) | 11 (7.5%) | 1.000 |
Percutaneous nephrolithotomye | 12 (8.2%) | 14 (9.6%) | 0.824 |
Past history | |||
Hypertensione | 42 (28.8%) | 41 (28.1%) | 0.889 |
Diabetese | 13 (8.9%) | 13 (8.9%) | 1.000 |
Degree of hydronephrosise | |||
No | 39 (26.7%) | 40 (27.4%) | 0.911 |
Mild | 53 (36.3%) | 52 (35.6%) | |
Moderate | 46 (31.5%) | 44 (30.1%) | |
Severe | 8 (5.48%) | 10 (6.8%) | |
Urinary leucocytee | |||
No | 37 (25.3%) | 33 (22.6%) | 0.555 |
Possible | 32 (21.9%) | 35 (24.0%) | |
Yes | 77 (52.8%) | 78 (53.4%) | |
Urinary nitritee | 13 (8.9%) | 12 (8.2%) | 1.000 |
Urine culturee | 21 (14.4%) | 23 (15.8%) | 0.864 |
E. coli | 10 | 11 | |
Enterococcus | 4 | 3 | |
Proteus mirabilis | 2 | 3 | |
Other | 5 | 6 | |
Stone size (mm)d | 23.9 ± 9.0 | 24.3 ± 7.1 | 0.462 |
Operation sitee | |||
Left | 74 (50.7%) | 77 (52.7%) | 0.810 |
Right | 72 (49.3%) | 69 (47.3%) | |
Stone location | |||
Ureteric stonee | 23 (15.8%) | 22 (15.1%) | 0.749 |
Renal and ureteric stonee | 26 (17.8%) | 25 (17.1%) | 1.000 |
Renal stonee | 84 (57.5%) | 85 (58.2%) | 1.000 |
Staghorn stonee | 13 (8.9%) | 14 (9.6%) | 1.000 |
cNormally distributed variable data analysed with paired-sample t test
dNonnormally distributed variable data analysed with the Wilcoxon-Mann–Whitney test
eCategorical variable data analysed with the McNemar test